

Strasbourg, 26 March 2025

T-MED (2025) OJ1

COMMITTEE OF THE PARTIES TO THE COUNCIL OF EUROPE CONVENTION ON THE COUNTERFEITING OF MEDICAL PRODUCTS AND SIMILAR CRIMES INVOLVING THREATS TO PUBLIC HEALTH

(MEDICRIME COMMITTEE)

9TH PLENARY MEETING

Opening at 09:30, Monday
Closing around 17:00, Tuesday

AGENDA

31 March – 1 April 2025
Palais de l'Europe, Room 11
Council of Europe

Document prepared by the MEDICRIME Secretariat
Directorate General I – Human Rights and Rule of Law



	1. Opening of the meeting
	2. Adoption of the draft agenda
T-MED (2025) OJ1 T-MED (2025) 01 T-MED (2025) OB1	Draft agenda Annotated agenda Order of Business
	3. Information by the Chair and the Secretariat
T-MED (2024) LD1	List of decisions of the 8th Plenary Meeting, 21-22 November 2024
	4. Tour de table – state Parties
	5. Monitoring of the MEDICRIME Convention and future work
	5.1 Country profile Questionnaire and its replies
See website	a) Status of play and answers received
Country Profile	b) Call for request to the following state Parties:
	Albania, Armenia, Belarus and Benin
	5.2 1st Thematic Monitoring round: <i>The protection of public health through the MEDICRIME Convention in times of pandemics</i>
See website	a) Status of play and answers received
	b) Call for request to the following non-answering Parties (Discussion)
Questionnaire	Albania, Belarus, Benin, Burkina Faso, Guinea, Moldova and Niger
Report sent to Parties	c) Final Report
	5.3 2nd Thematic Monitoring round: <i>Deposit and destruction measure of seized counterfeit¹ medical products, active substances, excipients, parts, materials, and accessories</i>
T-MED (2024) 05 T-MED (2024) 06 T-MED (2024) 07	Questionnaire. Explanatory Note to the 2 nd Thematic Monitoring Round Questionnaire Chronology- 2 nd Monitoring Round Deadline of 1 st Phase: 30th May 2025
T-MED (2025) 04	5.4 Lessons learned - Monitoring methodology

¹ [Guidance Note](#) to meaning of counterfeit being the same as falsified.

5.5 **MEDICRIME Strategy**

[MEDICRIME
Strategy
T-MED \(2024\)12](#)

Text of the Strategy 2024-2025

Interim implementation Report of the Strategy

Discussion about a New strategy

5.6 **Working Group: unauthorised removal, including theft, from the supply chain of medical products**

[T-MED \(2023\) 18](#)

Terms of reference

6. **Exchange of information, experiences and good practices**

6.1 **Exchange of views:**

6.1.1 **The work of the Committee of Experts on Minimising Public Health Risks Posed by Falsification of Medical Products and Similar Crimes (CD-P-PH/CMED)**

- Mr Chris McGUIRE, Chair of the CD-P-PH/CMED

6.1.2 **The fight against the counterfeiting of medicinal products in the Network of Official Medicines Control Laboratories (OMCLs)**

- Ms Marta MIQUEL, European Directorate for the Quality of Medicines and HealthCare

6.1.3 **The work of the Monitoring Group of the Anti-Doping Convention**

- Mr Michal RYNKOWSKI, Chair of the Monitoring Group of the Anti-Doping Convention

6.1.4 **The work of the Pompidou Group in combating organised crime related to drug trafficking**

[Terms of Reference](#)

- Ms Ardita ABDIU, Deputy Executive Secretary of the Pompidou Group

6.2 **National efforts and achievements in the fight against falsified medical products**

➤ **Ivory Coast:**

- Dr. Assane COULIBALY, Director General, AIRP - Ivorian Pharmaceutical Regulatory Authority.

➤ **Benin:**

- Dr. Yossounon CHABI, Director General, ABREP, Benin Agency for Medicines and Other Health Products

6.3 The Law Enforcement landscape perspective: Spain

- Mr Pedro Alberto ÁLVAREZ OTERO, Regional Customs Surveillance Area Special Delegation, Customs
- Mr Juan Pablo ARMENTEROS, General Commissariat of Judicial Police, Co-operation Division, National Police
- Mr Javier VALDENEBRO TINAUT, Head of the drug trafficking group in the Criminal Investigation Central Unit, Guardia Civil

6.4 Presentation of relevant activities by international governmental organisations and other observers**➤ Interpol**

- Ms Xie GUIQIU, Coordinator, Public Health & Pharmaceutical Crime Unit (TBC)

➤ ASOP- Europe

- Mr Mike ISLES, Director ASOP EU

➤ Pharmaceutical Security Institute (PSI)

- Mr Niall MCCARTHY, Regional Director EMEA

➤ Novartis

- Ms Lucy Hambloch, Associate Director- Anti-Falsified Medicines EME, Global Security

➤ Novo Nordisk

- TBC

7. Gender issues

[T-MED \(2025\) 03](#)

8. Artificial Intelligence**9. 24/7 Network****10. Technical Co-operation activities**

See [website](#)

10.1 CRIMFAMED Global Programme: latest developments

- Mr Henrique SOARES, Junior Project manager
- Mr Mark JACKSON, expert on diversion and falsified medical products and former head of the Medicines and Healthcare products Regulatory Agency's (MHRA) Enforcement Unit

[CRIMFAMED \(2025\)
11](#)

[HELP Training](#)**10.2 HELP Training****10.3 Call for voluntary contributions****11. Financing of the Committee of the Parties**[T-MED \(2025\) 08](#)**12. Elections****13. Information points****13.1 Participation of the MEDICRIME Committee in outside events**[Website](#)**13.2 Website - changes****13.3 New accessions to the MEDICRIME Convention****14. Any other business****15. Dates of the next Plenary meeting**

*

* *

Monday, 31 March 2025**Bilateral meetings:**

The following delegations are kindly requested to meet/contact the Secretariat during the Plenary meeting:

- Albania
- Moldova
- Guinea
- Niger

Tuesday, 1 April 2025

The Secretariat will held Bilateral meetings with the following delegations:

12h30 – 12h50 Benin, Burkina Faso